DNA damage and cancer immunotherapy: a STING in the tale
T Reisländer, FJ Groelly, M Tarsounas - Molecular cell, 2020 - cell.com
Cancer immunotherapies enhance anti-tumor immune responses using checkpoint
inhibitors, such as PD-1 or PD-L1 inhibitors. Recent studies, however, have extended the …
inhibitors, such as PD-1 or PD-L1 inhibitors. Recent studies, however, have extended the …
PARP inhibitors: Synthetic lethality in the clinic
CJ Lord, A Ashworth - Science, 2017 - science.org
PARP inhibitors (PARPi), a cancer therapy targeting poly (ADP-ribose) polymerase, are the
first clinically approved drugs designed to exploit synthetic lethality, a genetic concept …
first clinically approved drugs designed to exploit synthetic lethality, a genetic concept …
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the
immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we …
immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we …
[HTML][HTML] Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
M Jiang, K Jia, L Wang, W Li, B Chen, Y Liu… - … Pharmaceutica Sinica B, 2021 - Elsevier
Genomic instability remains an enabling feature of cancer and promotes malignant
transformation. Alterations of DNA damage response (DDR) pathways allow genomic …
transformation. Alterations of DNA damage response (DDR) pathways allow genomic …
The complementarity of DDR, nucleic acids and anti-tumour immunity
Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
S Vinayak, SM Tolaney, L Schwartzberg, M Mita… - JAMA …, 2019 - jamanetwork.com
Importance Poly (adenosine diphosphate–ribose) polymerase inhibitor and anti–
programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in …
programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in …
Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors
Simple Summary The tumor immune escape mechanisms are key factors in cancer
progression and metastasis. They are an undeniable hurdle for successful cancer treatment …
progression and metastasis. They are an undeniable hurdle for successful cancer treatment …
DNA damage and repair biomarkers of immunotherapy response
KW Mouw, MS Goldberg, PA Konstantinopoulos… - Cancer discovery, 2017 - AACR
DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor
DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic …
DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic …
The landscape of targeted therapies in TNBC
E Vagia, D Mahalingam, M Cristofanilli - Cancers, 2020 - mdpi.com
Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype
among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …
among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …
Current landscape of immunotherapy in breast cancer: a review
S Adams, ME Gatti-Mays, K Kalinsky, LA Korde… - JAMA …, 2019 - jamanetwork.com
Importance There is tremendous interest in using immunotherapy to treat breast cancer, as
evidenced by the more than 290 clinical trials ongoing at the time of this narrative review …
evidenced by the more than 290 clinical trials ongoing at the time of this narrative review …